Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro

Anti-Cancer Drugs

Volumn 24, Issue 1, 2013, Pages 32-42

  Li, Ming ^a   Li, Qian ^a   Zhang, Ya Hong ^a   Tian, Zhi Yong ^a   Ma, Hong Xia ^a   Zhao, Jin ^a   Xie, Song Qiang ^a   Wang, Chao Jie ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Akt signal; Apoptosis; Cell cycle; MTOR; Polyamine conjugate

Indexed keywords

3 AMINONAPHTHALIMIDE SPERMINE CONJUGATE; AMONAFIDE; ANTINEOPLASTIC AGENT; CASPASE; CYTOCHROME C; EFLORNITHINE; MAMMALIAN TARGET OF RAPAMYCIN; NAPHTHALIMIDE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN 14 3 3; PROTEIN BAD; PROTEIN BCL XL; PROTEIN KINASE B; SPERMIDINE; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME RELEASE; G1 PHASE CELL CYCLE CHECKPOINT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MALE; MICE; NAPHTHALIMIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPERMINE; TOR SERINE-THREONINE KINASES; TOXICITY TESTS;

EID: 84870937872     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328359affd     Document Type: Article

References (33)

1. Pogribny IP, Rusyn I, Beland FA. Epigenetic aspects of genotoxic and nongenotoxic hepatocarcinogenesis studies in rodents. Environ Mol Mutagen 2008; 49:9-15.
2. Alexia C, Fourmatgeat P, Delautier D, Groyer A. Insulin-like growth factor-I stimulates H4II rat hepatoma cell proliferation: dominant role of PI3-kinase/Akt signaling. Exp Cell Res 2006; 312:1142-1152.
3. Chong ZZ, Kang JQ, Maiese K. Akt1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9. Exp Cell Res 2004; 296:196-207.
4. Park S, Song J, Joe CO, Shin I. Akt stabilizes estrogen receptor alpha with the concomitant reduction in its transcriptional activity. Cell Signal 2008; 20:1368-1374.
5. Stoeltzing O, Meric-Bernstam F, Ellis LM. Intracellular signaling in tumor and endothelial cells: the expected and, yet again, the unexpected. Cancer Cell 2006; 10:89-91.
6. Clerkin JS, Naughton R, Quiney C, Cotter TG. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 2008; 266: 30-36.
7. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 2004; 1697:3-16.
8. Hu C, Solomon VR, Ulibarri G, Lee H. The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine. Bioorg Med Chem 2008; 16:7888-7893.
9. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007; 12:104-107.
10. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11:32-50.
11. Basuroy UK, Gerner EW. Emerging concepts in targeting the polyamine metabolic pathway in epithelial cancer chemoprevention and chemotherapy. J Biochem 2006; 139:27-33.
12. Cervelli M, Bellavia G, Fratini E, Amendola R, Polticelli F, Barba M, et al. Spermine oxidase (SMO) activity in breast tumor tissues and biochemical analysis of the anticancer spermine analogues BENSpm and CPENSpm. BMC Cancer 2010; 10:555.
13. Palmer AJ, Wallace HM. The polyamine transport system as a target for anticancer drug development. Amino Acids 2010; 38:415-422.
14. Wang C, Delcros JG, Biggerstaff J, Phanstiel O. Molecular requirements for targeting the polyamine transport system. Synthesis and biological evaluation of polyamine-anthracene conjugates. J Med Chem 2003; 46:2672-2682.
15. Wang C, Delcros JG, Biggerstaff J, Phanstiel O. Synthesis and biological evaluation of N1-(anthracen-9-ylmethyl)triamines as molecular recognition elements for the polyamine transporter. J Med Chem 2003; 46:2663-2671.
16. Casero RA Jr, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007; 6:373-390.
17. Tian ZY, Xie SQ, Du YW, Ma YF, Zhao J, Gao WY, et al. Synthesis, cytotoxicity and apoptosis of naphthalimide polyamine conjugates as antitumor agents. Eur J Med Chem 2009; 44:393-399.
18. Xie SQ, Li Q, Zhang YH, Wang JH, Mei ZH, Zhao J, et al. NPC-16, a novel naphthalimide polyamine conjugate, induced apoptosis and autophagy in human hepatoma HepG2 cells and Bel-7402 cells. Apoptosis 2011; 16: 27-34.
19. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T Helper 17 cells. Hepatology 2010; 51: 154-164.
20. Palmer AJ, Ghani RA, Kaur N, Phanstiel O, Wallace HM. A putrescine- anthracene conjugate: a paradigm for selective drug delivery. Biochem J 2009; 424:431-438.
21. Barret JM, Kruczynski A, Vispé S, Annereau JP, Brel V, Guminski Y, et al. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res 2008; 68:9845-9853.
22. Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010; 19:919-930.
23. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des 2010; 16:1410-1416.
24. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010; 16:4325-4330.
25. Jiang BH, Liu LZ. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 2008; 1784:150-158.
26. Blanco-Aparicio C, Cañamero M, Cecilia Y, Pequeño B, Renner O, Ferrer I, et al. Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS One 2010; 5:e9305.
27. Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, et al. Novel pathway in Bcr-Abl signal transduction involves Aktindependent, PLC-g 1-driven activation of mTOR/p70S6-kinase pathway PLC-g 1-driven activation of p70S6-K pathway in CML. Oncogene 2010; 29:739-751.
28. García-Sáez AJ, Fuertes G, Suckale J, Salgado J. Permeabilization of the outer mitochondrial membrane by Bcl-2 proteins. Adv Exp Med Biol 2010; 677:91-105.
29. Hockenbery DM. Targeting mitochondria for cancer therapy. Environ Mol Mutagen 2010; 51:476-489.
30. Holst CM, Johansson VM, Alm K, Oredsson SM. Novel anti-apoptotic effect of Bcl-2: prevention of polyamine depletion-induced cell death. Cell Biol Int 2008; 32:66-74.
31. Bratton MR, Duong BN, Elliott S, Weldon CB, Beckman BS, Mclachlan JA, et al. Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. Int J Oncol 2010; 37:541-550.
32. Kuo CT, Hsu MJ, Chen BC, Chen CC, Teng CM. Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction. Toxicol Lett 2008; 177: 48-58.
33. Ingrassia L, Lefranc F, Kiss R, Mijatovic T. Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem 2009; 16:1192-1213.